Crystal form of a compound, composition thereof and method of use
By discovering and preparing novel crystal forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazin-1-carbamoylpyridin-3-yl ester, It also improves its stability and bioavailability through characterization technology, solves the problem of predicting and preparing crystalline forms of drug compounds, and realizes the stability and marketing of drug products.
Patent Information
- Application Number
- CN201980060119.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-13
- Filing Date
- 2019-09-12
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-09-12
AI Technical Summary
The prior art is difficult to predict and prepare the crystalline forms of drug compounds, resulting in problems with the stability and bioavailability of drug products, affecting drug development and marketing promotion.
A novel crystal form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carbamoylpyridin-3-yl ester was discovered and prepared. Its physical properties are characterized by X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis and other technologies, and corresponding pharmaceutical compositions are prepared to improve the stability and solubility of the drug.
The discovery and preparation of new crystal forms of drugs has been realized, the physical and chemical stability of drugs has been improved, the control of their bioavailability and production process has been enhanced, and the stability and marketing problems of drug products have been solved.
Smart Images

Figure GDA0004989361420000031 
Figure GDA0004989361420000161 
Figure GDA0004989361420000171
Abstract
Description
Technical Field
[0001] Provided herein is a crystalline form of a compound, a composition thereof, and a method of use thereof. Provided herein is a solid form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. Also provided herein are pharmaceutical compositions comprising such solid forms and methods for treating, preventing, and controlling various conditions. Background Art
[0002] Many compounds can exist in different crystalline forms or polymorphs that exhibit different physical, chemical, and spectral properties. For example, certain polymorphs of a compound may dissolve more easily in a particular solvent, may flow more easily, or may be more easily compressed than other polymorphs. See, e.g., P. DiMartino et al., J. Thermal Anal., 48:447-458 (1997). In the case of drugs, certain solid forms may be more bioavailable than other solid forms, while other solid forms may be more stable under certain manufacturing, storage, and biological conditions.
[0003] It is known in the pharmaceutical art that the polymorphic form of a compound affects, for example, the solubility, stability, flowability, friability and compressibility of the compound, as well as the safety and efficacy of a drug product containing the compound. See, for example, Knapman, K. Modern Drug Discoveries, 2000, 53. Therefore, the discovery of new polymorphic forms of a drug can provide a variety of advantages.
[0004] The identification and selection of solid forms of pharmaceutical compounds is complex because changes in solid form may affect a variety of physical and chemical properties, which may provide benefits or disadvantages in processing, formulation, stability, bioavailability, storage, handling (e.g., transportation), and other important pharmaceutical properties. Depending on the product and its mode of administration, useful pharmaceutical solids include crystalline solids and amorphous solids. Amorphous solids are characterized by a lack of long-range structural order, while crystalline solids are characterized by structural periodicity. The type of pharmaceutical solid required depends on the specific application; amorphous solids are sometimes selected based on, for example, enhanced dissolution characteristics, while crystalline solids may be desirable for properties such as physical or chemical stability.
[0005] The importance of discovering polymorphs through Ritonavir TMThe case of , an HIV protease inhibitor formulated as a soft gel capsule, was highlighted. Approximately two years after the product was launched, unexpected precipitation of a new, less soluble polymorph in the formulation necessitated the withdrawal of the product from the market until a more consistent formulation could be developed (see SR Chemburkar et al., Org. Process Res. Dev., (2000) 4:413-417).
[0006] It is noteworthy that it is impossible to predict in advance whether crystalline forms of a compound will exist, let alone how to successfully prepare them (see, e.g., Braga and Grepioni, 2005, "Making crystals from crystals: a green route to crystal engineering and polymorphism," Chem. Commun.: 3635-3645 (with respect to crystal engineering, if the instructions are not very precise and / or if other external factors affect the process, the results can be unpredictable); Jones et al., 2006, Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement," MRS Bulletin 31: 875-879 (currently, it is generally impossible to computationally predict the number of observable polymorphs for even the simplest molecules); Price, 2004, "The computational prediction of pharmaceutical crystal structures and polymorphism," Advanced Drug Delivery Reviews 56: 301-319 ("Price"); and Bernstein, 2004, "Crystal Structure Prediction and Polymorphism," ACA Transactions 39: 14-23 (There is still a great deal of learning and work to be done before one can state with any degree of confidence the ability to predict crystal structure, let alone polymorphs).
[0007] The variety of possible solid forms creates a diversity of potential physical and chemical properties for a given drug compound. The discovery and selection of solid forms is important for developing effective, stable, and marketable drug products.
[0008] (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester is a compound that acts as a dual MAGL and FAAH inhibitor and is useful for treating various disorders.
[0009] The synthesis of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate has been described in PCT / US2018 / 022049, filed on March 12, 2018.
[0010] A novel crystalline form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester is described herein. The novel polymorph of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester can be further developed for use in formulations for treating various diseases and can result in numerous formulation, manufacturing and therapeutic benefits. Summary of the invention
[0011] Provided herein are crystalline forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. Also provided herein are pharmaceutical compositions comprising crystalline forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. Also provided herein are methods for treating or preventing a variety of diseases and conditions, comprising administering to a patient a therapeutically effective amount of a crystalline form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester.
[0012] Also provided herein are methods for preparing, isolating and characterizing crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 A representative X-ray powder diffraction (XRPD) pattern of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form A is provided.
[0014] Figure 2 Provided are a representative differential scanning calorimetry (DSC) thermogram and a representative thermogravimetric analysis (TGA) thermogram of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form A.
[0015] Figure 3A representative dynamic vapor sorption (DVS) graph of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form A is provided.
[0016] Figure 4 Provided are representative XRPD spectra of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A before and after DVS experiments.
[0017] Figure 5 Provided are representative XRPD spectra of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A before and after stability testing under accelerated conditions.
[0018] Figure 6 A representative nuclear magnetic resonance (NMR) spectrum of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form A is provided.
[0019] Figure 7 A representative XRPD spectrum of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form B is provided.
[0020] Figure 8 A representative DSC thermogram and a representative TGA thermogram of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form B are provided.
[0021] Fig. 9 A representative XRPD spectrum of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form C is provided.
[0022] Fig.10 Provided are representative DSC and TGA thermograms of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C.
[0023] Fig.11 A representative XRPD spectrum of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form D is provided.
[0024] Fig.12Representative DSC and TGA thermograms of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D are provided.
[0025] Fig.13 A representative XRPD spectrum of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form E is provided.
[0026] Fig.14 Representative DSC and TGA thermograms of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form E are provided.
[0027] definition
[0028] As used herein, unless otherwise specified, the compound referred to herein as (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate corresponds to the compound of formula (I) described below.
[0029]
[0030] (R)-5-Carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate can be obtained by standard synthetic methods (e.g., see PCT / US2018 / 022049).
[0031] Unless otherwise indicated, the term "crystalline" and related terms used herein, when used to describe a substance, component, product or form, means that the substance, component, product or form is substantially crystalline, for example, as determined by X-ray diffraction. (See, for example, Remington's Pharmaceutical Sciences, 20th edition, Lippincott Williams & Wilkins, Philadelphia PA, 173 (2000); The United States Pharmacopeia, 37th edition, 503-509 (2014)).
[0032] As used herein, unless otherwise indicated, the terms "about" and "approximately" when used in conjunction with the dose, amount or weight percentage of the ingredients of the composition or dosage form, mean a dose, amount or weight percentage recognized by those of ordinary skill in the art as providing a pharmacological effect comparable to that obtained from the specified dose, amount or weight percentage. In certain embodiments, the terms "about" and "approximately" when used herein consider a dose, amount or weight percentage to be within 30%, within 20%, within 15%, within 10% or within 5% of the specified dose, amount or weight percentage.
[0033] As used herein, unless otherwise indicated, the terms "about" and "approximately", when used in conjunction with a value or range of values provided to characterize a particular solid form (e.g., such as, for example, a particular temperature or temperature range describing a melting, dehydration, desolvation, or glass transition temperature; a change in mass, such as a change in mass with temperature or humidity; solvent or water content, such as expressed in mass or percentage; or a peak position, such as in analysis by, for example, IR or Raman spectroscopy or XRPD), indicate that the value or range of values may vary to the extent deemed reasonable by one of ordinary skill in the art while still describing the solid form. Techniques for characterizing crystalline and amorphous forms include, but are not limited to, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), single crystal X-ray diffraction, vibrational spectroscopy, such as infrared (IR) and Raman spectroscopy, solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies. In certain embodiments, the terms "about" and "approximately" when used herein, indicate that a value or range of values can vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the value or range of values. In the context of molar ratios, "about" and "approximately" mean that a value or range of values may vary within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the value or range of values. It should be understood that the values of the peaks of an X-ray powder diffraction pattern may vary between different machines or between different samples, and therefore the quoted values are not to be interpreted as absolute, but rather with an allowable variability, such as ±0.2 degrees 2θ (°2θ) or greater. For example, in some embodiments, the values of the XRPD peak positions may vary by up to ±0.2 degrees 2θ while still describing a specific XRPD peak.
[0034] As used herein, unless otherwise indicated, "substantially physically pure" solid forms are substantially free of other solid forms. In certain embodiments, substantially physically pure crystalline forms include less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or 0.01% of one or more other solid forms based on weight. The detection of other solid forms can be completed by any method apparent to those of ordinary skill in the art, including but not limited to diffraction analysis, thermal analysis, elemental combustion analysis and / or spectral analysis.
[0035] As used herein, unless otherwise indicated, a "substantially chemically pure" solid form is substantially free of other compounds (i.e., chemical impurities). In certain embodiments, a substantially chemically pure solid form comprises less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or 0.01% of one or more other compounds by weight. Detection of other compounds can be accomplished by any method apparent to one of ordinary skill in the art, including but not limited to chemical analysis methods, for example, mass spectrometry, spectral analysis, thermal analysis, elemental combustion analysis and / or chromatographic analysis.
[0036] As used herein, unless otherwise indicated, a compound, solid form, or composition that is "substantially free" of another compound, solid form, or composition means that in certain embodiments, the compound, solid form, or composition contains less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2% 0.1%, 0.05%, or 0.01% by weight of an additional compound, solid form, or composition.
[0037] As used herein, and unless otherwise indicated, the terms "anhydrate" and "anhydrous" refer to a solid form of a substance that does not contain water in its crystal lattice.
[0038] As used herein, unless otherwise indicated, the terms "treat," "treating," and "treatment" refer to eradication or amelioration of a disease or disorder / disorder, or one or more symptoms associated with a disease or disorder. In certain embodiments, the term refers to minimizing the spread or worsening of such a disease or disorder due to administration of one or more prophylactic or therapeutic agents to a subject suffering from a disease or disorder. In some embodiments, the term refers to administration of a compound provided herein with or without administration of other additional active agents after the onset of symptoms of a particular disease.
[0039] Unless otherwise indicated, the term "composition" as used herein is intended to encompass a product containing one or more specified ingredients (and in one or more specified amounts, if indicated), as well as any product resulting directly or indirectly from the combination of one or more specified ingredients in one or more specified amounts. "Pharmaceutically acceptable" means that the diluent, excipient or carrier in the formulation must be compatible with one or more of the other ingredients of the formulation and not deleterious to the recipient thereof.
[0040] Unless otherwise indicated, the term "subject" is defined herein to include animals, such as mammals, including but not limited to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In specific embodiments, the subject is a human.
[0041] Unless otherwise indicated, if there is a discrepancy between the depicted chemical structure of a compound provided herein and the chemical name of the compound provided herein, the chemical structure shall control. DETAILED DESCRIPTION
[0042] Provided herein are solid forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. In certain embodiments, the solid form is crystalline. In certain embodiments, the solid form is a single component solid form. In certain embodiments, the solid form is an anhydrous form.
[0043] Crystalline forms of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate can be prepared by methods described herein, including those described in the Examples below, or by techniques known in the art, including heating, cooling, freeze drying, lyophilization, solvent evaporation, solvent recrystallization, antisolvent addition, slurry recrystallization, rapid cooling, slow cooling, exposure to solvents and / or water, and drying. The particle size of the resulting solid form may vary, for example, from nanometer size to millimeter size, which can be controlled, for example, by varying crystallization conditions, such as crystallization rate and / or crystallization solvent system, or by particle size reduction techniques, such as grinding, milling, micronization, or sonication.
[0044] While not wishing to be bound by any particular theory, crystalline forms of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are characterized by physical properties suitable for pharmaceutical and therapeutic dosage forms, such as stability, solubility, and dissolution rate. In addition, while not wishing to be bound by any particular theory, crystalline forms of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are characterized by physical properties (e.g., density, compressibility, hardness, morphology, cleavage, viscosity, solubility, water absorption, electrical properties, thermal behavior, solid state reactivity, physical stability, and chemical stability) that affect specific processes (e.g., yield, filtration, washing, drying, grinding, mixing, tableting, flowability, dissolution, formulation, and lyophilization) that produce certain crystalline forms suitable for use in producing dosage forms. Such properties can be determined using specific analytical chemistry techniques as described herein and known in the art, including solid state analytical techniques (eg, X-ray diffraction, microscopy, spectroscopy, and thermal analysis).
[0045] Certain embodiments herein provide compositions comprising crystalline (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate.
[0046] Certain embodiments provide methods of using these compositions to treat, prevent, or manage diseases and conditions, including but not limited to diseases and conditions associated with MAGL and / or FAAH activity.
[0047] Certain embodiments herein provide methods of using crystalline forms of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate to treat, prevent or manage pain, neurological disorders, anxiety, inflammatory bowel disease, neuropathic pain, and the proliferation and migration of cancer cells.
[0048] Certain embodiments herein provide crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A.
[0049] In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be obtained from methanol. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be obtained from isopropyl acetate. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be obtained from a 9:1 ethanol / water mixture. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be obtained from toluene.
[0050] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be characterized by X-ray powder diffraction analysis.
[0051] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having an X-ray powder diffraction pattern comprising peaks at 16.5, 20.1 and 22.3 degrees 2θ ± 0.2 degrees 2θ.
[0052] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having an X-ray powder diffraction pattern comprising peaks at 16.4, 20.1 and 22.3 degrees 2θ ± 0.2 degrees 2θ.
[0053] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having an X-ray powder diffraction pattern comprising peaks at 18.1, 20.1 and 22.3 degrees 2θ ± 0.2 degrees 2θ.
[0054] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 9.9, 19.9 and 24.6 degrees 2θ ± 0.2 degrees 2θ.
[0055] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 9.9, 19.9 and 24.7 degrees 2θ ± 0.2 degrees 2θ.
[0056] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen of the following approximate positions: 9.9, 13.3, 13.9, 14.8, 16.4, 18.0, 19.9, 20.1, 22.3, 23.0, 24.4, 24.6, 26.9, and 29.3 degrees 2θ. In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0057] In certain embodiments, crystalline (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate Form A is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one of the following approximate positions: 9.9, 13.4, 14.0, 14.2, 14.9, 16.0, 16.5, 17.3, 18.1, 19.3, 19.9, 20.1, 20.6, 21.4, 22.3, 23.1, 24.1, 24.7, 27.0, 27.2, and 29.3 degrees 2θ. In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0058] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having an X-ray powder diffraction pattern corresponding to Figure 1 A representative X-ray powder diffraction pattern is depicted in FIG.
[0059] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A can be characterized by thermal analysis.
[0060] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 113°C.
[0061] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 112°C.
[0062] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 112°C.
[0063] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 111°C.
[0064] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester having a differential scanning calorimetry thermogram corresponding to Figure 2 Representative differential scanning calorimetry thermogram depicted in .
[0065] In one embodiment, anhydrous crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided.
[0066] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a thermogravimetric analysis thermogram comprising a weight loss of less than about 1.22% upon heating from about 25°C to about 100°C.
[0067] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a thermogravimetric analysis thermogram comprising a weight loss of less than about 1.0% upon heating from about 30°C to about 150°C.
[0068] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a thermogravimetric analysis thermogram comprising a weight loss of less than about 0.1% upon heating from about 30°C to about 150°C.
[0069] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A having a thermogravimetric analysis thermogram corresponding to Figure 2 Representative thermogravimetric analysis thermogram depicted in .
[0070] In one embodiment, substantially physically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided.
[0071] In one embodiment, substantially chemically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided.
[0072] In one embodiment, a pharmaceutical composition comprising crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided.
[0073] Certain embodiments herein provide crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B.
[0074] In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B can be obtained from a 9:1 acetonitrile / water mixture. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B can be obtained from an ethyl acetate / n-heptane mixture, methyl acetate, acetone, or dichloromethane.
[0075] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B can be characterized by X-ray powder diffraction analysis.
[0076] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having an X-ray powder diffraction pattern comprising peaks at 16.2, 18.2, and 19.2 degrees 2θ ± 0.2 degrees 2θ.
[0077] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 15.1, 18.7 and 20.1 degrees 2θ ± 0.2 degrees 2θ.
[0078] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, Form B, is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the following approximate positions: 15.1, 16.2, 17.9, 18.2, 18.7, 19.2, 20.1, 21.1, 24.3, 25.0, 27.4, and 27.6 degrees 2θ. In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0079] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having an X-ray powder diffraction pattern corresponding to Figure 7 A representative X-ray powder diffraction pattern is depicted in FIG.
[0080] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B can be characterized by thermal analysis.
[0081] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 95°C.
[0082] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 91°C.
[0083] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a differential scanning calorimetry thermogram corresponding to Figure 8 Representative differential scanning calorimetry thermogram depicted in .
[0084] In one embodiment, anhydrous crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is provided.
[0085] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a thermogravimetric analysis thermogram comprising a weight loss of less than about 2.5% upon heating from about 30°C to about 100°C.
[0086] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a thermogravimetric analysis thermogram comprising a weight loss of less than about 1.0% upon heating from about 30°C to about 150°C.
[0087] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a thermogravimetric analysis thermogram comprising a weight loss of less than about 0.1% upon heating from about 30°C to about 150°C.
[0088] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B having a thermogravimetric analysis thermogram corresponding to Figure 8 Representative thermogravimetric analysis thermogram depicted in .
[0089] In one embodiment, substantially physically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is provided.
[0090] In one embodiment, substantially chemically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is provided.
[0091] In one embodiment, a pharmaceutical composition comprising crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B is provided.
[0092] Certain embodiments herein provide crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C.
[0093] In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C can be obtained from a 1:3 chloroform / hexane mixture. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester can be obtained from a 1:1 ethanol / water mixture. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester can be obtained from a 3:1 acetonitrile / water mixture. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester can be obtained by slurrying Form B in FaSSIF. In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester can be obtained by slurrying Form B in FeSSIF.
[0094] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C can be characterized by X-ray powder diffraction analysis.
[0095] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having an X-ray powder diffraction pattern comprising peaks at 18.0, 20.0, and 21.0 degrees 2θ ± 0.2 degrees 2θ.
[0096] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 12.3, 16.8 and 25.5 degrees 2θ ± 0.2 degrees 2θ.
[0097] In certain embodiments, crystalline (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate Form C is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two of the following approximate positions: 12.3, 14.1, 14.7, 14.8, 15.5, 15.7, 16.2, 16.8, 17.1, 18.0, 18.2, 18.5, 19.5, 20.0, 20.5, 21.0, 21.4, 22.8, 24.6, 25.5, 25.9, and 29.6 degrees 2θ. In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0098] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having an X-ray powder diffraction pattern corresponding to Fig. 9 A representative X-ray powder diffraction pattern is depicted in FIG.
[0099] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C can be characterized by thermal analysis.
[0100] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 99°C.
[0101] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 98°C.
[0102] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having a differential scanning calorimetry thermogram corresponding to Fig.10 Representative scanning calorimetry thermogram depicted in .
[0103] In one embodiment, anhydrous crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided.
[0104] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided, the thermogravimetric analysis thermogram of which comprises a weight loss of about 0.149% upon heating from about 30°C to about 150°C.
[0105] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C, whose thermogravimetric analysis thermogram comprises a weight loss of less than about 1.0% upon heating from about 30°C to about 150°C.
[0106] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided, whose thermogravimetric analysis thermogram comprises a weight loss of about 0.15% upon heating from about 30°C to about 150°C.
[0107] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C having a thermogravimetric analysis thermogram corresponding to Fig.10 Representative thermogravimetric analysis thermogram depicted in .
[0108] In one embodiment, substantially physically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided.
[0109] In one embodiment, substantially chemically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided.
[0110] In one embodiment, a pharmaceutical composition comprising crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C is provided.
[0111] Certain embodiments herein provide crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D.
[0112] In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D can be obtained by slurrying Form B in methyl tert-butyl ether (MTBE).
[0113] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D can be characterized by X-ray powder diffraction analysis.
[0114] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having an X-ray powder diffraction pattern comprising peaks at 13.4, 21.0 and 23.8 degrees 2θ ± 0.2 degrees 2θ.
[0115] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 18.3, 26.7 and 29.5 degrees 2θ ± 0.2 degrees 2θ.
[0116] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen approximate positions: 13.4, 14.0, 14.8, 16.1, 16.8, 18.0, 18.3, 18.6, 19.5, 19.8, 20.7, 21.0, 22.8, 23.8, 24.4, 26.7, and 29.5 degrees 2θ. In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0117] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having an X-ray powder diffraction pattern corresponding to Fig.11 A representative X-ray powder diffraction pattern is depicted in FIG.
[0118] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D can be characterized by thermal analysis.
[0119] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 101°C.
[0120] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 99°C.
[0121] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having a differential scanning calorimetry thermogram corresponding to Fig.12 Representative differential scanning calorimetry thermogram depicted in .
[0122] In one embodiment, anhydrous crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided.
[0123] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided, whose thermogravimetric analysis thermogram comprises a weight loss of about 0.054% upon heating from about 30°C to about 150°C.
[0124] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D, which has a thermogravimetric analysis thermogram comprising less than about 0.1% weight loss upon heating from about 30°C to about 150°C.
[0125] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D having a thermogravimetric analysis thermogram corresponding to Fig.12 Representative thermogravimetric analysis thermogram depicted in .
[0126] In one embodiment, substantially physically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided.
[0127] In one embodiment, substantially chemically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided.
[0128] In one embodiment, a pharmaceutical composition comprising crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D is provided.
[0129] Certain embodiments herein provide crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E.
[0130] In one embodiment provided herein, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E can be obtained from a chloroform / hexane mixture.
[0131] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E can be characterized by X-ray powder diffraction analysis.
[0132] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having an X-ray powder diffraction pattern comprising peaks at 17.8, 21.3, and 22.8 degrees 2θ ± 0.2 degrees 2θ.
[0133] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided, wherein the X-ray powder diffraction spectrum further includes peaks at 15.8, 18.4 and 21.9 degrees 20±0.2 degrees 2θ.
[0134] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is characterized by XRPD peaks located at one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the following approximate positions: 10.9, 12.7, 15.8, 17.2, 17.8, 18.4, 19.721.3, 21.9, 22.8, 24.2, and 25.6 degrees 2θ. In certain embodiments, crystalline (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate is characterized by an XRPD pattern having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 peaks that match the peaks in the representative XRPD patterns provided herein.
[0135] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having an X-ray powder diffraction pattern corresponding to Fig.13 A representative X-ray powder diffraction pattern is depicted in FIG.
[0136] In certain embodiments, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E can be characterized by thermal analysis.
[0137] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having a differential scanning calorimetry thermogram comprising an endotherm maximum at about 104°C.
[0138] In one embodiment, provided is crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having a differential scanning calorimetry thermogram comprising an endotherm with an onset at about 102°C.
[0139] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having a differential scanning calorimetry thermogram corresponding to Fig.14 Representative differential scanning calorimetry thermograms are depicted in FIG.
[0140] In one embodiment, anhydrous crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided.
[0141] In one embodiment, crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided, the thermogravimetric analysis thermogram of which comprises a weight loss of about 0.37% upon heating from about 30°C to about 150°C.
[0142] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E, which has a thermogravimetric analysis thermogram comprising a weight loss of less than about 1.0% upon heating from about 30°C to about 150°C.
[0143] In one embodiment, there is provided crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E having a thermogravimetric analysis thermogram corresponding to Fig.14 Representative thermogravimetric analysis thermogram depicted in .
[0144] In one embodiment, substantially physically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided.
[0145] In one embodiment, substantially chemically pure crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided.
[0146] In one embodiment, a pharmaceutical composition comprising crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E is provided.
[0147] Pharmaceutical composition
[0148] Provided herein are pharmaceutical compositions and single unit dosage forms comprising a crystalline form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. Also provided herein are methods of preparing pharmaceutical compositions and single unit dosage forms comprising a crystalline form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. For example, in certain embodiments, a single dosage form comprising or prepared using crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester provided herein can be suitable for oral, mucosal (including rectal, nasal or vaginal), parenteral (including subcutaneous, intramuscular, bolus, intraarterial or intravenous), sublingual, transdermal, buccal or topical administration.
[0149] In certain embodiments, pharmaceutical compositions and dosage forms provided herein comprise a crystalline form of (R)-5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Certain embodiments herein provide pharmaceutical compositions and dosage forms comprising a crystalline form of 5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, wherein the crystalline form of 5-carbamoylpyridin-3-yl 2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate is substantially pure. Certain embodiments herein provide pharmaceutical compositions and dosage forms comprising a crystalline form of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester provided herein, wherein the composition or dosage form is substantially free of other crystalline solid forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester and / or amorphous solid forms of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester. The pharmaceutical compositions and dosage forms provided herein generally also comprise one or more pharmaceutically acceptable excipients, diluents, or carriers.
[0150] The single unit dosage forms provided herein are suitable for oral or parenteral (e.g., subcutaneous, intravenous, bolus, intramuscular or intraarterial) administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules; such as soft elastic gelatin capsules; powders and sterile solids that can be reconstituted to provide a liquid dosage form suitable for parenteral administration to a patient.
[0151] The composition, shape, and type of dosage forms provided herein generally vary depending on their use. Compared to oral dosage forms used to treat the same disease or condition, parenteral dosage forms may contain smaller amounts of one or more of the active ingredients they contain. These and other ways in which specific dosage forms encompassed by the present invention differ from one another will be apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
[0152] Typical pharmaceutical compositions and dosage forms include one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art, including but not limited to the manner in which the dosage form is administered to the patient. For example, oral dosage forms such as tablets may contain excipients that are not suitable for parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredient in the dosage form.
[0153] Like the amount and type of excipients, the amount and specific type of active ingredient in the dosage form can also vary according to factors such as, but not limited to, the route of its administration to the patient. However, the typical dosage form provided herein is administered in a single dose once a day in the morning, or in divided doses throughout the day, within the range of about 0.1 mg to about 1,000 mg per day. More specifically, the daily dose can be administered twice, three times or four times a day in equal divided doses. Specifically, the daily dose range can be about 0.1 mg to about 500 mg per day, more specifically, about 0.1 mg to about 200 mg per day. The daily dose range can be 1 mg, 2 mg, 3 mg, 4 mg or 5 mg. When controlling the patient, the therapy can start with a lower dose (possibly about 1 mg to about 25 mg), and if necessary, increase to up to about 200 mg to about 1,000 mg per day in a single dose or divided doses, depending on the patient's overall response.
[0154] Oral dosage form
[0155] The pharmaceutical compositions suitable for oral administration provided herein can be present in discrete dosage forms, such as, but not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain a predetermined amount of active ingredient and can be prepared by pharmaceutical methods well known to those skilled in the art. See generally Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton Pa. (1990).
[0156] Typical oral dosage forms provided herein are prepared by thoroughly mixing one or more active ingredients with at least one excipient according to conventional pharmaceutical mixing techniques. Depending on the form of the formulation required for administration, the excipient can take a variety of forms. For example, excipients suitable for oral liquid or aerosol dosage forms include, but are not limited to, water, ethylene glycol, oil, alcohol, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrants.
[0157] If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such dosage forms may be prepared by any pharmaceutical method. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and thoroughly mixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation form as necessary.
[0158] For example, tablets can be prepared by compression or molding. Compressed tablets can be prepared by compressing the active ingredient (optionally mixed with an excipient) in a free-flowing form such as a powder or granules in a suitable machine. Molded tablets can be prepared by molding a mixture of a powdered compound moistened with an inert liquid diluent in a suitable machine.
[0159] Examples of excipients that can be used for oral dosage forms of the present invention include, but are not limited to, adhesives, fillers, disintegrants, and lubricants. Adhesives suitable for pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch or other starches, gelatin, natural and synthetic gums such as gum arabic, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and derivatives thereof (e.g., ethylcellulose, cellulose acetate, carboxymethylcellulose calcium, sodium carboxymethylcellulose), polyvinyl pyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methylcellulose (e.g., No. 2208, No. 2906, No. 2910), microcrystalline cellulose and mixtures thereof.
[0160] Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof. The binder or filler in the pharmaceutical composition of the present invention typically accounts for about 50 to about 99% by weight of the pharmaceutical composition or dosage form.
[0161] Suitable forms of microcrystalline cellulose include, but are not limited to, AVICEL-PH-101 TM 、AVICEL-PH-103 TM 、AVICEL RC-581TM 、AVICEL-PH-105 TM (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, Pa.), and mixtures thereof. A particular adhesive is available as AVICEL RC-58 TM A mixture of microcrystalline cellulose and sodium carboxymethyl cellulose is sold. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103 TM and Starch 1500LM TM .
[0162] Disintegrants are used in the compositions provided herein to provide tablets that disintegrate when exposed to an aqueous environment. Tablets containing too much disintegrant may disintegrate in storage, and tablets containing too little disintegrant may not disintegrate at a desired rate or under desired conditions. Therefore, a sufficient amount of disintegrant should be used to form a solid oral dosage form of the present invention, and the amount of the disintegrant is neither too much nor too little, and the release of the active ingredient will not be adversely changed. The amount of the disintegrant used varies according to the type of formulation, and is easily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions contain about 0.5 to about 15% by weight of disintegrant, particularly about 1 to about 5% by weight of disintegrant.
[0163] Disintegrants that can be used in the pharmaceutical compositions and dosage forms provided herein include, but are not limited to, agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pregelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
[0164] Lubricants that can be used in the pharmaceutical compositions and dosage forms provided herein include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, and mixtures thereof. Other lubricants include, for example, syloid silica gel (AEROSIL 200 TM, manufactured by WR Grace Co. of Baltimore, Md.), coagulated aerosol of synthetic silica (sold by Degussa Co. of Plano, Tex.), CAB-O-SIL TM (a fumed silica product sold by Cabot Co. of Boston, Mass.), and mixtures thereof. If used at all, lubricants are generally used in amounts less than about 1% by weight of the pharmaceutical composition or dosage form into which they are incorporated.
[0165] Parenteral Dosage Forms
[0166] Parenteral dosage forms can be administered to a patient by a variety of routes, including, but not limited to, subcutaneous, intravenous (including bolus), intramuscular, and intraarterial injections. Because their administration typically bypasses the patient's natural defenses against contaminants, parenteral dosage forms are preferably sterile or can be sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, anhydrous products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
[0167] Those skilled in the art are familiar with suitable vehicles that can be used to provide parenteral dosage forms. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethanol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[0168] Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms provided herein.
[0169] Combination therapy
[0170] Combination therapy is also contemplated herein, e.g., co-administration of the disclosed compounds and additional active agents as part of a specific treatment regimen intended to provide a beneficial effect through the combined action of these therapeutic agents. The beneficial effects of the combination include, but are not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents. The combined administration of these therapeutic agents is typically carried out over a defined period of time (typically weeks, months, or years, depending on the combination selected). Combination therapy is intended to include administration of multiple therapeutic agents in a sequential manner, i.e., wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents or at least two of the therapeutic agents in a substantially simultaneous manner.
[0171] For example, substantially simultaneous administration is achieved by administering to the subject a single formulation or composition (e.g., a tablet or capsule with a fixed ratio of each therapeutic agent) or a plurality of single formulations (e.g., capsules) for each therapeutic agent. Sequential administration or substantially simultaneous administration of each therapeutic agent is achieved by any suitable route, including but not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption by mucosal tissue. The therapeutic agents are administered by the same route or different routes. For example, the first therapeutic agent of the selected combination is administered by intravenous injection, while the other therapeutic agents of the combination are administered orally. Alternatively, for example, all therapeutic agents are administered orally, or all therapeutic agents are administered by intravenous injection.
[0172] Combination therapy also includes further combined administration of the above therapeutic agents with other biologically active ingredients and non-drug therapies. In the case where the combination therapy also includes non-drug therapy, the non-drug therapy is performed at any appropriate time, as long as the beneficial effects of the combined action of the therapeutic agent and the non-drug therapy are achieved. For example, in appropriate cases, when the non-drug therapy is temporarily removed from the administration of the therapeutic agent (possibly for several days or even weeks), a beneficial effect can still be obtained.
[0173] The components of the composition are administered to the patient simultaneously or sequentially. It should be understood that the components are present in the same pharmaceutically acceptable carrier and are therefore administered simultaneously. Alternatively, the active ingredients are present in separate pharmaceutical carriers, such as conventional oral dosage forms that are administered simultaneously or sequentially.
[0174] For example, for the intended pain treatment, the disclosed compounds are co-administered with another pain therapeutic agent such as an opioid, a cannabinoid receptor (CB-1 or CB-2) modulator, a COX-2 inhibitor, acetaminophen and / or a nonsteroidal anti-inflammatory drug. Other therapeutic agents co-administered, for example, for the treatment of pain, include morphine, codeine, hydromorphone, hydrocodone, oxymorphone, fentanyl, tramadol and levorphanol.
[0175] Other therapeutic agents contemplated for co-administration include aspirin, naproxen, ibuprofen, salicylate, diflunisal, dexibuprofen, fenoprofen, ketoprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, celecoxib, parecoxib, rimonabant, and / or etoricoxib.
[0176] Example
[0177] Example 1: (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A
[0178] Form A was obtained with several solvents including methanol, isopropyl acetate, and a 9:1 mixture of ethanol / water. Form A was also prepared by slurrying the starting material (a mixture of Form A / C) in toluene at room temperature for 1 day. The NMR spectrum of Form A indicated trace amounts of toluene on the surface. The HPLC purity of a sample of Form A was measured to be 99.87 area %. The differential scanning calorimetry thermogram of Form A included an endotherm onset at about 111-112° C. and a maximum endotherm at about 113° C. (Figure 2A). Figure 2 Thermogravimetric analysis of Form A includes a weight loss of less than about 0.1% upon heating from about 30°C to about 100°C, indicative of an anhydrous material (e.g. Figure 2 shown).
[0179] Dynamic vapor sorption (DVS) isotherms of Form A were collected between 0% RH and 95% RH at 25°C (see Figure 2). Figure 3 ). A water uptake of 0.05% was observed at 25°C / 80% RH. XRPD comparison showed that no form change was observed for Form A after DVS testing (as shown in Figure 4 shown).
[0180] The Form A sample exhibited good physical and chemical stability under accelerated conditions of 25°C / 60% RH and 40°C / 75% RH for 3 months. The X-ray powder diffraction spectra of Form A before and after the accelerated conditions were compared as shown in FIG. Figure 5 Tables 1 and 2 (different XRPD instruments and samples; peaks below a certain amplitude are omitted for clarity) show the XRPD peaks of Form A.
[0181] Table 1. XRPD peaks of Form A.
[0182]
[0183] Table 2. XRPD peaks of Form A.
[0184]
[0185] Example 2: (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form B
[0186] Form B was obtained with a 9:1 mixture of acetonitrile / water. Form B was also obtained by liquid vapor diffusion of ethyl acetate / n-heptane mixtures and evaporation in neat methyl acetate, acetone, or dichloromethane. The XRPD peaks of Form B are shown in Table 3. When heated from about 30°C to about 100°C, a weight loss of less than 1.0% was observed. DSC results showed a sharp endotherm starting at 91°C and a maximum endotherm at about 95°C. Based on the low TGA weight loss and a single sharp DSC endotherm, Form B was assumed to be a dehydrate.
[0187] Table 3. XRPD peaks of Form B.
[0188]
[0189] Example 3: (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form C
[0190] When Form B was slurried in FaSSIF-v2 or FeSSIF-v2 at 37°C for 2 hours, Form C was obtained. Form C can also be obtained with a 1:3 chloroform / hexane mixture. DSC shows a maximum endotherm at about 99°C and TGA shows a weight loss of less than about 0.15% when heated from about 30°C to about 150°C, indicating that Form C is a dehydrate. The XRPD peaks of Form C are shown in Table 4.
[0191] Table 4. XRPD peaks of Form C.
[0192]
[0193]
[0194] Example 4: (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form D
[0195] Form D can be obtained by slurrying Form B in MTBE at room temperature for 10 days. DSC shows a maximum endotherm at about 101°C, and TGA shows a weight loss of about 0.054% when heated from about 30°C to about 150°C, indicating that Form D is a dehydrate. The XRPD peaks of Form D are shown in Table 5.
[0196] Table 5. XRPD peaks of Form D.
[0197]
[0198]
[0199] Example 5: (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form E
[0200] Form E can be obtained by slurrying Form C in a chloroform / hexane mixture at room temperature for 9 days. DSC shows a maximum endotherm at about 104°C, and TGA shows a weight loss of about 0.37% when heated from about 30°C to about 150°C, indicating that Form E is a dehydrate. The XRPD peaks of Form E are shown in Table 6.
[0201] Table 6. XRPD peaks of Form E.
[0202]
[0203] Example 6: Stability and solubility testing
[0204] The solution stability test of Form A was carried out to evaluate the substantial degradation of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester in physiologically relevant media. A solution of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester (1 mg / mL) was prepared in acetonitrile / water (50 / 50 v / v). Test medium (1990 μL) was added to a vial. The test medium evaluated included buffer pH 1-8, simulated gastric fluid (SGF), fasted state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF). Stock solution (10 μL) was added to a vial containing medium. The mixture was stirred to fully mixed and transferred to an HPLC vial, which was placed in an automatic sampler maintained at 37 °C. The vial was injected repeatedly every 4 hours for 24 hours. The results are shown in Table 7. The solubility is shown in Table 8.
[0205] Table 7. Solution Chemical Stability Data of Crystalline (R)-2-Methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A at 37°C
[0206]
[0207] Table 8. Solubility of crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A in physiologically relevant media (37°C).
[0208]
[0209]
[0210] Example 7: Stress Polymorph Screening
[0211] Form B was used as the starting form for stress polymorph screening. Tests were performed in various solvents at room temperature or lower. The results are shown in Table 9.
[0212] Table 9. Stress polymorph screening at room temperature or lower using Form B as the starting form.
[0213]
[0214] *Initially a clear solution was observed; stirring was continued at 4 °C for 1 day and then at room temperature for 9 days
[0215] Example 8: Polymorph Screening
[0216] Polymorph screening was performed at 50° C. Solutions starting with Form B were prepared at a concentration of approximately 50 mg in 100 to 300 μL of the solvents listed in Table 10. The solutions were stirred at 50° C. for 24 hours.
[0217] Table 10. Polymorph screening at 50°C.
[0218] condition state result <![CDATA[H2O]]> Serum Form A MTBE Serum Form A CPME Clear solution Evaporation of transparent film only
[0219] Example 9: Freeze-drying studies
[0220] An attempt was made to produce an amorphous material by lyophilizing Form B. Form B was lyophilized overnight at -40°C in the DPD core region using a LyoSys 3 freeze dryer. The results are shown in Table 11.
[0221] Table 11. Lyophilization attempts.
[0222] experiment Form / Solvent result 1 <![CDATA[Form B in 240 mg of approximately 4:1 H2O:MeCN]]> Form A 2 <![CDATA[Form B in about 3:2 H2O:MeCN at 240 mg]]> Form B 3 <![CDATA[Form B in 240 mg of approximately 2:1 H2O:MeCN]]> Form B
[0223] Example 10: Solubility study of Form A
[0224] At 37 ° C, the solubility of Form A in FaSSIF-v2 and FeSSIF-v2 was evaluated at 2 hours and 24 hours. About 40 mg of Form A sample was added to 2.0 mL of the corresponding biological medium to form a suspension, and then vibrated at 500 rpm at 37 ° C. After 2 hours and 24 hours, the supernatant was separated by centrifugation (7000 rpm for 5 minutes), then filtered through a 0.45 mm PTFE membrane, and tested according to HPLC concentration and pH value. The residual solid is characterized by XRPD. As summarized in Table 12, the 24-hour solubility of Form A in FaSSIF-v2 and FeSSIF-v2 was measured to be 0.063 mg / mL and 1.1 mg / mL, respectively. The XRPD spectra show that no form changes are observed after solubility assessment.
[0225] Table 12. Summary of the solubility evaluation of Form A at 37°C.
[0226]
[0227] Example 11: Accelerated Solid-State Stability Study of Form A
[0228] Form A was subjected to solid state stability evaluation at 25°C / 60%RH and 40°C / 75%RH (accelerated conditions). The detailed procedures for the stability evaluation are listed below:
[0229] 1) Weigh approximately 30 mg of Form A sample into each 3 mL vial;
[0230] 2) Use Cover the vial with a needle Poke 15 holes on top;
[0231] 3) placing the vials in a stabilization chamber at 25°C / 60% RH or 40°C / 75% RH; and
[0232] 4) After 2, 4 and 6 weeks and 3 months, samples were taken for XRPD, TGA, DSC, HPLC purity and assay testing.
[0233] The results of the solid state stability evaluation are summarized in Table 13. The impurities are summarized in Table 14. According to the characterization results of XRPD, TGA and DSC, no obvious form change or HPLC purity decrease was observed after 3 months under both conditions. Therefore, the Form A sample showed good physical and chemical stability for 3 months under 25°C / 60%RH and 40°C / 75%RH conditions.
[0234] Table 13. Summary of stability results.
[0235]
[0236] *: Chiral purity of starting material was tested after storage at -20°C for approximately 3 months
[0237] Table 14. Summary of Area % of impurities in solid state stability studies.
[0238]
[0239] --:<0.05.
[0240]
[0241]
[0242] Example 12: Solid State Characterization of Form A
[0243] A summary of baseline solid-state characterization results (including pKa, partition coefficient (log D7.4) measurements, and 2-hour equilibrium solubility in FaSSIF and FeSSIF (Form 2) for crystalline (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester Form A is provided herein. Table 15 summarizes all the results obtained. First, by The pKa values were predicted and then tested by Sirius T3 (range 2.0 to 12.0) (triplicate). Log D7.4 was measured by shake flask method with a solvent system of pH 7.4 phosphate buffer and n-octanol. Meanwhile, the 2-hour equilibrium solubility of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester in FaSSIF and FeSSIF (Formula 2) was 0.12 mg / mL and 0.080 mg / mL, respectively.
[0244] Table 15. Summary of pKa, Log D and solubility results.
[0245]
[0246] The predicted and detected pKa values range from 2.0 to 12.0
[0247] N / A: Not measured.
[0248] Example 13: Solubility of Form A
[0249] The approximate solubility of Form A was determined in 20 solvent systems at room temperature. Approximately 2 mg of sample was added to a 3 mL glass vial. The solvents in Table 16 were then added dropwise (100 μL / step) to the vial until the solids were visually dissolved or a total volume of 2 mL was reached. The solubility results summarized in Table 16 were used to guide solvent selection in the screening experimental design.
[0250] Table 16. Approximate solubility of Form A at room temperature
[0251]
[0252] Example 14: Solubility of Form B
[0253] At 37 ° C, the solubility of Form B in FaSSIF-v2 and FeSSIF-v2 was evaluated at 2 hours. About 10 to 20 mg of Form B sample was added to 0.8 mL of the corresponding biologically relevant medium to form a suspension, and then vibrated at 500 rpm at 37 ° C. After 2 hours, the supernatant was separated by centrifugation (7200 rpm for 5 minutes), then filtered through a 0.45 mm PTFE membrane, and tested according to HPLC concentration and pH value. The residual solid was characterized by XRPD. As summarized in Table 17, after solubility evaluation, Form B was converted into a new form (Form C), and the solubility in FaSSIF-v2 and FeSSIF-v2 was measured to be 0.12 mg / mL and 0.080 mg / mL, respectively.
[0254] Table 17. Summary of the solubility evaluation of Form B at 37°C
[0255]
[0256] Approximately 55 to 90 mg of Form B was added to a 4 mL glass vial. The solvent list in Table 18 was added to each vial. The samples were stirred for 3 minutes prior to visual solubility assessment.
[0257] Table 18. Summary of the solubility evaluation of Form B at room temperature.
[0258]
[0259] Example 15: Antisolvent Addition Experiment
[0260] Antisolvent addition experiments were performed. A total of 8 antisolvent addition experiments were performed. About 15 mg of Form A was dissolved in 0.5 mL of solvent to obtain a clear solution, which was magnetically stirred and then antisolvent was added to induce precipitation until the total amount of antisolvent reached 10 mL. The precipitate was separated for XRPD analysis. The clear solution was transferred to -20 ° C and kept for 5 hours. The results summarized in Table 19 show that only Form A was obtained.
[0261] Table 19. Summary of antisolvent addition experiments.
[0262]
[0263] *: These solids were obtained by slurry at -20°C
[0264] Example 16: Slow evaporation experiment
[0265] Slow evaporation experiments were performed under 6 conditions. Approximately 15 mg of Form A was dissolved in 1.0 mL of the corresponding solvent in a 3 mL glass vial. The clear solution visible to the naked eye was evaporated at room temperature to induce precipitation. The isolated solid was used for XRPD analysis. The results summarized in Table 20 indicate that Form A, Form B, and amorphous were obtained.
[0266] Table 20. Summary of slow evaporation experiments.
[0267]
[0268] Example 17: Slow Cooling Experiment
[0269] Slow cooling experiments were performed in two solvent systems. About 50 mg of Form A was suspended in 0.5-1.0 mL of solvent in a 3 mL glass vial at room temperature. The suspension was then heated to 50 ° C, equilibrated for about 2 hours, and filtered into a new vial. The filtrate was slowly cooled to 5 ° C at a rate of 0.1 ° C / minute. The clear solution was transferred to -20 ° C, then evaporated to dryness at room temperature, and then the solid was tested by XRPD. The results summarized in Table 21 show that only Form A was obtained.
[0270] Table 21. Summary of slow cooling experiments.
[0271]
[0272] *: These solids were obtained by evaporation at room temperature
[0273] Example 18: Slurry conversion experiment
[0274] Slurry conversion experiments were performed. Slurry conversion experiments were performed in 7 different solvent systems at room temperature. About 20 mg of Form A was suspended in 0.3-0.9 mL of solvent in an HPLC glass vial. After stirring the suspension at room temperature for 5 days, the remaining solid was separated for XRPD analysis. After stirring, a clear solution was obtained, in which the anti-solvent n-heptane was added to induce crystallization. The results summarized in Table 22 indicate that only Form A was obtained.
[0275] Table 22. Summary of slurry conversion experiments performed at room temperature.
[0276]
[0277] *: Solid was obtained after anti-solvent addition of n-heptane.
[0278] Slurry conversion experiments were also performed at 50°C in 3 different solvent systems. Approximately 20 mg of Form A was suspended in 0.4-1.0 mL of solvent in an HPLC glass vial. After the suspension was stirred at 50°C for 5 days, the remaining solid was separated for XRPD analysis. After stirring, a clear solution was obtained, to which the anti-solvent n-heptane was added to induce crystallization. The results summarized in Table 23 indicate that only Form A was obtained.
[0279] Table 23. Summary of slurry conversion experiments conducted at 50°C.
[0280]
[0281] *: Solid was obtained after anti-solvent addition of n-heptane.
[0282] Example 19: Liquid Vapor Diffusion Experiment
[0283] Liquid vapor diffusion experiments were performed. Four liquid vapor diffusion experiments were performed. About 15 mg of Form A was dissolved in 0.5 mL of solvent to obtain a clear solution in a 3 mL vial. The solution was then placed in a 20 mL vial containing 4 mL of anti-solvent. The 20 mL vial was sealed with a lid and the organic vapor was kept interacting with the solution at room temperature. The precipitate was separated for XRPD analysis. The results summarized in Table 24 show that Form A and Form B were obtained.
[0284] Table 24. Summary of liquid vapor diffusion experiments.
[0285]
[0286] Example 20: Interconversion studies
[0287] Interconversion studies of crystalline forms were conducted. In order to understand the thermodynamic stability relationship between Form A and Form B, competitive slurry experiments were performed in water and toluene at room temperature and 50°C. Prior to the study, Form A was used to saturate the corresponding solvent, which was then filtered to obtain a nearly saturated solution. Equal amounts of Form A and Form B samples were weighed and then mixed with the prepared nearly saturated solution to form a new suspension, which was magnetically stirred (~1000rpm) at room temperature and 50°C. As summarized in Table 25, Form A was obtained after slurrying for 1 to 3 weeks at room temperature and 50°C, indicating that Form A is thermodynamically more stable than Form B from room temperature to 50°C.
[0288] Table 25. Thermodynamic stability studies.
[0289] Starting form Solvent (v / v) temperature Final form Form A+B <![CDATA[H2O / PhMe]]> RT Form A Form A+B <![CDATA[H2O / PhMe]]> 50℃ Form A
[0290] Example 21: Competitive slurry study
[0291] Competitive slurry studies of all known forms A to E were conducted in water at room temperature to understand the thermodynamic stability relationship between these forms. Water was saturated with Form A and then filtered to obtain a nearly saturated solution. An equal amount of each form (A to E) was weighed and then mixed with the prepared nearly saturated solution to form a new suspension, which was magnetically stirred (~1000 rpm) at room temperature for 7 days. The solid was isolated and analyzed by XRPD to obtain Form A, indicating that Form A is the most thermodynamically stable form at room temperature.
[0292] Example 22: Steam induced crystallization experiment
[0293] A total of 9 different experiments were performed. About 100 mg of Form B was placed in a 4 mL glass vial, which was then placed in a 20 mL vial containing 4 mL of antisolvent. The 20 mL vial was sealed with a lid and the organic vapor was kept at room temperature to interact with the solid. After 7 to 10 days, the wet solid was separated and analyzed by XRPD. The results summarized in Table 26 show that Form A and Form B were obtained.
[0294] Table 26. Summary of steam induced crystallization experiments
[0295] condition result Ethanol Form A DMSO Form A Isopropyl acetate Form A Methyl acetate Form B THF Transparent film after evaporation <![CDATA[CH2Cl2]]> Form B Cyclohexanone Form A dimethylformamide Form A n-Butyl acetate Form A
[0296] Characterization methods
[0297] Samples generated as described in the solid form screening are typically analyzed by X-ray powder diffraction (XRPD). XRPD is performed on PANalytical Empyrean and X'Pert3 X-ray powder diffractometers using Cu Kα radiation at 1.54A. In general, the positions of XRPD peaks are expected to vary individually on a measurement-by-measurement basis by about ±0.2° 2θ. Generally, as understood in the art, two XRPD spectra match each other if a characteristic peak of the first spectrum is located at approximately the same position as a characteristic peak of the second spectrum. As understood in the art, determining whether two XRPD spectra match or whether individual peaks in two XRPD spectra match may require consideration of individual variables and parameters, such as, but not limited to, preferred orientation, phase impurities, crystallinity, particle size, changes in diffractometer instrument settings, changes in XRPD data collection parameters, and / or changes in XRPD data processing, among others. Whether two spectra match can be determined by eye and / or computer analysis. Examples of XRPD spectra collected and analyzed using these methods and parameters are provided herein, for example, Figure 1 shown.
[0298] PANalytical Emptyrean
[0299] Scan mode: continuous
[0300] Detector: D / teXUltra
[0301] Divergence slit: Automatic
[0302] Start angle: 3 degrees
[0303] Stop angle: 40 degrees
[0304] Step size: 0.0200 degrees
[0305] Scan time(s): 5.00 degrees / minute
[0306] Entrance slit: 1 / 2 degree
[0307] Receiving slit #1: 8.000mm
[0308] Receiving slit #2: 13.000mm
[0309] wavelength: Intensity ratio Kα2 / Kα1: 0.50; 40 kV, 44 mA.
[0310] X'Pert3
[0311] Scan mode: continuous
[0312] Divergence slit: 1 / 8°
[0313] Starting angle: 3 degrees
[0314] Stop angle: 40 degrees.
[0315] Step size: 0.0263 degrees
[0316] Scan step time (s): 46.665
[0317] Test time: about 5 minutes
[0318] wavelength: Intensity ratio Kα2 / Kα1: 0.50.
[0319] Differential Scanning Calorimetry (DSC) analysis was performed on a TA Instruments Q200 / Q2000. Approximately 5 mg of sample was placed in a tared DSC crimped / open aluminum pan and the weight of the sample was accurately recorded. Nitrogen was used as the purge gas and the heating rate was 10°C / min. Examples of DSC thermograms collected and analyzed using these methods and parameters are provided herein, such as Figure 2 shown.
[0320] Thermogravimetric analysis (TGA) was performed on a TA Instruments Q500 / Q5000. Approximately 10 mg of sample was placed on an open aluminum pan, accurately weighed and loaded into the TGA furnace. Nitrogen was used as the purge gas and the heating rate was 10 °C / min. Examples of TGA thermograms collected and analyzed using these methods and parameters are provided herein, such as Figure 2 shown.
[0321] Dynamic vapor sorption (DVS) was performed on a Surface Measurement Systems DVS Intrinsic. Relative humidity at 25°C was calibrated to the deliquescence point of LiCl, Mg(NO3)2, and KCl. Sample size was 10 mg to 20 mg. Gas and flow rate was nitrogen, 200 mL / min; dm / dt: 0.002% / min.
[0322] HPLC was performed using an Agilent 1100 / 1260. Analysis of Form A was determined using a Phenomenex Gemini C18, 150x4.6 mm, 3 μm (column). The mobile phase was 0.1% formic acid in water; the flow rate was 1.0 mL / min; the column temperature was 40°C; and the UV detector was at 270 nm. Analysis of Form B was determined using a Kinetex 5μμm EVO C18, 150x4.6 mm, 5μm (column). The mobile phase was 0.1% formic acid in acetonitrile; the flow rate was 1.0 mL / min; the column temperature was 40°C; and the UV detector was at 210 nm.
[0323] Using DMSO d6 Proton NMR was collected on a Bruker 400 NMR spectrometer.
[0324] The above embodiments are intended to be exemplary only, and those skilled in the art will recognize, or will be able to determine using only routine experimentation, many equivalents to the specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of this disclosure and are covered by the appended claims.
[0325] Citation or identification of any reference in this application does not constitute an admission that such reference is available as prior art.The full scope of the present disclosure can be better appreciated with reference to the appended claims.
Claims
1. Form A of (R)-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylic acid 5-carbamoylpyridin-3-yl ester, the X-ray powder diffraction spectrum of the form A comprising peaks at 9.9, 18.1, 20.1, 22.3, and 24.7 degrees 2θ±0.2 degrees 2θ.
2. The crystalline form A according to claim 1, wherein the X-ray powder diffraction spectrum of the crystalline form A corresponds to the X-ray powder diffraction spectrum in Figure 1.
3. The crystalline form A according to claim 1 or 2, wherein the crystalline form A comprises less than 10% by weight of one or more other solid forms.
4. The crystalline form A according to claim 1 or 2, comprising less than 10% by weight of one or more other compounds.
5. A pharmaceutical composition comprising the crystalline form A according to claim 1 or 2.
6. Use of a composition for preparing a medicament for treating pain in a subject, the composition comprising the crystalline form A according to any one of claims 1 to 4.
7. Use of a composition for preparing a medicament for treating a neurological disorder in a subject, the composition comprising the crystalline form A according to any one of claims 1 to 4.
8. Use of a composition for preparing a medicament for treating anxiety in a subject, the composition comprising the crystalline form A according to any one of claims 1 to 4.
9. Use of a composition for preparing a medicament for treating inflammatory bowel disease in a subject, the composition comprising the crystalline form A according to any one of claims 1 to 4.
10. Use of a composition for preparing a medicament for treating neuropathic pain in a subject, the composition comprising the crystalline form A according to any one of claims 1 to 4.
11. Use of a composition for preparing a medicament for treating proliferation and migration of cancer cells in a subject, the composition comprising the crystalline form according to any one of claims 1 to 4.
